

# AbbVie Pipeline Update

February 2026



abbvie

# AbbVie R&D Pipeline

## Phase 1

- ABBV-243 ( $\beta$ 7) Autoimmune Diseases
- ABBV-319 (CD19 ADC) SLE, Sjorgren's Disease
- ABBV-547 (IL-23) Autoimmune Diseases
- ABBV-619 (CD19 CAR-T) Autoimmune Diseases
- ABBV-701 (TL1A) IBD
- ABBV-324 (GPC3 ADC) HCC / SQ-NSCLC
- ABBV-461\* + CLBR001 (CAR-T) Breast Cancer
- ABBV-514 (CCR8) Solid Tumors
- ABBV-711 (PARP7i) Solid Tumors
- ABBV-901 (FR $\alpha$  ADC) Ovarian Cancer
- ABBV-969 (PSMA/STAP1 ADC) mCRPC
- Alveltamig\* (DLL3/DLL3/CD3) SCLC
- RC148\*<sup>#</sup> (PD-1/VEGF) Solid Tumors
- Temab-A (c-Met ADC) Solid Tumors
- ABBV-101 (BTK Degrader) R/R NHL
- ABBV-319 (CD19 ADC) Heme Tumors
- ABBV-525 (MALT1i) Heme Tumors
- ABBV-2001\* (CD38/BCMA/CD3) R/R MM
- Etentamig (BCMA/CD3) MM Combinations
- SIM0500\* (GPRC5D/BCMA/CD3) R/R MM
- Surzetoclax (ABBV-453) (BCL2i) R/R MM
- UB-VV111\* (CD19 CAR-T) LBCL, CLL
- ABBV-1042 (M4 Agonist) Bipolar Mania
- ABBV-1758 (3pE-A $\beta$ ) Alzheimer's Disease
- Emraclidine (M4 PAM) Psychosis
- ABBV-6628 (C5) Geographic Atrophy
- ABBV-295 (Amylin) Obesity
- ABBV-141 (LPAR1) SSC & IPF
- ABBV-722 (LPAR1) SSC & IPF

## Phase 2

- ABBV-382 ( $\alpha$ 4 $\beta$ 7) + Skyrizi (IL-23) CD
- ABBV-8736 (TREM1) CD
- Lutikizumab (IL-1 $\alpha$ /1 $\beta$ ) Atopic Dermatitis
- Lutikizumab (IL-1 $\alpha$ /1 $\beta$ ) + Ravagalimab (CD40) RA
- Lutikizumab (IL-1 $\alpha$ /1 $\beta$ ) + Skyrizi (IL-23) PsA
- Lutikizumab (IL-1 $\alpha$ /1 $\beta$ ) + Skyrizi (IL-23) CD
- ABBV-706 (SEZ6 ADC) SCLC
- Elahere (FR $\alpha$  ADC) PSOC (420)
- Elahere (FR $\alpha$  ADC) Ovarian Cancer (FLORENZA)
- IMGN-151 (FR $\alpha$  ADC) Gynecologic Cancers
- Livmoniplimab (GARP+TGF $\beta$ 1) NSCLC
- Temab-A (c-Met ADC) CRC
- Temab-A (c-Met ADC) GEA
- Temab-A (c-Met ADC) Met-Amplified Solid Tumors
- Temab-A (c-Met ADC) NSCLC
- Epkinly\* (CD20/CD3) B-Cell NHL
- Epkinly\* (CD20/CD3) R/R CLL and Richter's Syndrome
- Etentamig (BCMA/CD3) AL Amyloidosis
- Pivekimab Sunirine (CD123 ADC) AML
- ABBV-932\* (D2/D3 Agonist) Bipolar Depression
- ABBV-932\* (D2/D3 Agonist) GAD
- ABBV-1354 (KOR Antagonist) Bipolar Depression
- ABBV-1354 (KOR Antagonist) MDD
- ABBV-2002 (PAR-2) Migraine Prevention
- Bretisilocin (5-HT2AR Agonist) MDD
- Emraclidine (M4 PAM) Schizophrenia
- ABBV-RGX-314\* (NAV AAV8 Anti-VEGF Fab) wAMD Suprachoroidal Delivery
- ABBV-RGX-314\* (NAV AAV8 Anti-VEGF Fab) DR Suprachoroidal Delivery
- AGN-193408 (Prostamide 408 SR) Glaucoma
- ABBV-142 (LPAR1) IPF

## Registrational / Phase 3

- Lutikizumab (IL-1 $\alpha$ /1 $\beta$ ) HS
- Rinvoq (JAK1i) Alopecia Areata
- Rinvoq (JAK1i) HS
- Rinvoq (JAK1i) SLE
- Elahere (FR $\alpha$  ADC) PSOC (GLORIOSA)
- Temab-A (c-Met ADC) 3L+ CRC
- Epkinly\* (CD20/CD3) 1L DLBCL
- Epkinly\* (CD20/CD3) R/R DLBCL
- Epkinly\* (CD20/CD3) 1L FL
- Etentamig (BCMA/CD3) 3L+ MM
- Qulipta (CGRP) Menstrual Migraine Prevention
- Ubrevely (CGRP) Menstrual Migraine Prevention
- ABBV-RGX-314\* (NAV AAV8 Anti-VEGF Fab) wAMD Subretinal Delivery
- Armour Thyroid (T3T4) Hypothyroidism

## Submitted

- Rinvoq (JAK1i) Vitiligo
- Pivekimab Sunirine (CD123 ADC) BPDCN
- Qulipta (CGRP) Migraine Acute Treatment (INTL)
- Tavapadon (D1/D5 Partial Agonist) Parkinson's Disease
- TrenibotE Glabellar Lines
- Reproxalap (RASP)\* Dry Eye Disease

- Immunology
- Oncology
- Neuroscience
- Aesthetics
- Eye Care
- Targeted Investment

As of February 4, 2026

Excludes devices in development

\*AbbVie Partnered assets

<sup>#</sup>RC148 is part of announced licensing agreement with RemeGen. Closing subject to satisfaction or waiver of customary closing conditions.

# AbbVie - Anticipated Key Pipeline Events

|   | 2026   | 2027   |
|---|--|--|
| <b>Regulatory Approvals</b>             | <p>Rinvoq Vitiligo<br/>                     Epkinly 2L FL (INTL)<br/>                     Pivekimab Sunirine BPDCN<br/>                     Qulipta Migraine Acute Treatment (INTL)<br/>                     Tavapadon Parkinson's Disease<br/>                     TrenibotE Glabellar Lines</p>  | <p>Rinvoq Alopecia Areata<br/>                     Skyrizi Crohn's Disease Subcutaneous Induction<br/>                     Epkinly 1L DLBCL<br/>                     Epkinly 2L DLBCL Transplant Ineligible<br/>                     Qulipta Menstrual Migraine Prevention (EU)<br/>                     Ubrelvy Menstrual Migraine Prevention (US)</p>  |
| <b>Regulatory Submissions</b>           | <p>Rinvoq Vitiligo<br/>                     Rinvoq Alopecia Areata<br/>                     Skyrizi Crohn's Disease Subcutaneous Induction<br/>                     Epkinly 1L DLBCL<br/>                     Epkinly 2L DLBCL Transplant Ineligible<br/>                     Qulipta Menstrual Migraine Prevention (EU)</p>   | <p>Lutikizumab Hidradenitis Suppurativa<br/>                     Rinvoq Hidradenitis Suppurativa<br/>                     Rinvoq Systemic Lupus Erythematosus<br/>                     Elahere 2L PSOC Maintenance<br/>                     Etentamig Monotherapy 3L MM<br/>                     Ubrelvy Menstrual Migraine Prevention (US)<br/>                     ABBV-RGX-314 wAMD Subretinal Delivery</p>   |
| <b>Ph3/Registrational Data Readouts</b> | <p>Lutikizumab Ph3 Hidradenitis Suppurativa<br/>                     Rinvoq Ph3 Hidradenitis Suppurativa<br/>                     Skyrizi Ph3 Crohn's Disease Subcutaneous Induction<br/>                     Epkinly Ph3 1L DLBCL<br/>                     Epkinly Ph3 2L DLBCL Transplant Ineligible<br/>                     Etentamig Monotherapy Ph3 3L MM (ORR)<br/>                     Qulipta Ph3 Menstrual Migraine Prevention<br/>                     Ubrelvy Ph3 Menstrual Migraine Prevention</p>  | <p>Rinvoq Ph3 Systemic Lupus Erythematosus<br/>                     Elahere Ph3 2L PSOC Maintenance<br/>                     Temab-A Monotherapy Ph3 3L+ CRC<br/>                     ABBV-RGX-314 Ph3 wAMD Subretinal Delivery</p>  |
| <b>Early-Stage Data Readouts</b>        | <p>ABBV-382 + Skyrizi Ph2 CD<br/>                     Lutikizumab + Skyrizi Ph2 CD<br/>                     Lutikizumab + Ravagalimab Ph2 RA<br/>                     ABBV-969 Ph1 mCRPC<br/>                     ABBV-2001 Ph1 MM<br/>                     Etentamig Ph1 2L MM Combinations<br/>                     IMGN-151 Ph2 PROC<br/>                     Livmoniplimab Ph2 1L NSCLC<br/>                     Temab-A Ph2 comboTx 2L CRC<br/>                     ABBV-932 Ph2 Bipolar Depression<br/>                     Bretisilocin Ph2 MDD<br/>                     Emraclidine Ph2 Schizophrenia<br/>                     Emraclidine Ph1 Psychosis<br/>                     ABBV-295 Ph1 Obesity</p> | <p>ABBV-319 Ph1 SLE/Sjorgren's Disease<br/>                     ABBV-619 Ph1 RA/SLE<br/>                     Lutikizumab + Skyrizi Ph2 PsA<br/>                     ABBV-514 Ph1 Solid Tumors<br/>                     Etentamig Ph1 1L MM Combinations<br/>                     Surzetoclast Ph1 MM<br/>                     Temab-A Ph2 comboTx 1L CRC<br/>                     Temab-A Ph2 comboTx 1L GEA<br/>                     Temab-A Ph2 comboTx 1L NSCLC<br/>                     Temab-A Ph2 comboTx 1L PDAC<br/>                     Temab-A Ph2 monoTx 2L NSCLC EGFR-mutant<br/>                     ABBV-932 Ph2 Generalized Anxiety Disorder<br/>                     ABBV-1354 Ph2 MDD<br/>                     ABBV-2002 Ph2 Migraine Prevention<br/>                     ABBV-RGX-314 Ph2 wAMD Suprachoroidal Delivery</p> |

As of February 4, 2026

# AbbVie's Partnered Assets

- ABBV-461 developed in partnership with Calibr.
- ABBV-932 developed in partnership with Gedeon Richter.
- ABBV-2001 developed in partnership with IGI.
- ABBV-RGX-314 co-developed by REGENXBIO and AbbVie.
- Alveltamig developed by Suzhou Zelgen Biopharmaceuticals. AbbVie holds an exclusive option to develop and commercialize Alveltamig.
- Epkinly developed in partnership with Genmab.
- RC148 is part of announced licensing agreement with RemeGen. Closing subject to satisfaction or waiver of customary closing conditions. RC148 to be developed in partnership with RemeGen.
- Reproxalap currently developed by Aldeyra. AbbVie holds an exclusive option to license, co-develop, and co-commercialize reproxalap.
- SIM0500 developed by Simcere Zaiming. AbbVie holds an exclusive option to develop and commercialize SIM0500.
- UB-VV111 developed by Umoja Biopharma. AbbVie holds an exclusive option to develop and commercialize UB-VV111.